Update on the Management of Ascites and Hepatorenal Syndrome

Hepatorenal syndrome (HRS) is one of many potential causes of acute kidney injury in patients with acute or chronic liver disease. Accurate diagnosis and effective therapies are the best tools to stem the flow of advancing injury to both the liver and the kidneys. This highly focused seminar will provide that information. It will be delivered at level that is appropriate for these generalists and their nurse practitioners, physician assistants, and other members of their care team.
When Mar 10, 2022 06:30 AM to
Sep 07, 2022 08:45 AM
Where Various Dates and Locations - See Below
Contact Name
Contact Phone (253) 432-4023
Add event to calendarvCal
iCal


Target Audience
Gastroenterologists, Internists, Hepatologists, as well as related advanced-practice clinicians and nurse specialists. 

Program Agenda (Times May Vary)

7:00am
Introduction to Seminar, Learning Objectives, Accreditation and Faculty

7:05am

  • Introduction to Hepatorenal Syndrome in patients with liver disease
  • Overview of disease progression How cirrhosis can lead to portal hypertension, ascites, kidney disease and hepatorenal syndrome
  • The diagnosis and treatment of ascites
  • The role of Paracentesis and the importance of reducing sodium levels
  • The role of Albumin infusion in serial paracentesis for refractory ascites
  • Transjugular intrahepatic portosystemic shunt (TIPS) – candidates, procedures and risk.
  • When advancing cirrhosis impairs kidney function and confirming HRS
  • The diagnosis and management of acute kidney infection
  • Terlipressin and Norepinephrine: Mechanism of Action, Potency and Method of Administration
  • The importance of the CONFIRM trial
  • Treatment and Prognosis of HRS patients
  • The role of primary care clinicians in the early diagnosis and treatment of cirrhosis and hepatorenal syndrome

7:50am
Questions, Discussion and Recommendation for better care outcomes

8:00am
Adjourn

Learning Objectives
As a result of participating in this activity, participants should be able to:
1. Describe the causes, symptoms, and treatment for ascites.
2. Advice patients of the dangers of cirrhosis and the importance of fluid management.
3. Develop realistic sodium reduction approaches for patients with mild ascites.
4. Evaluate the benefits vs risks of a TIPS procedure.
5. Know how liver disease impacts kidney health and the warning signs of HRS.
6. Differentiate between Type 1 and Type 2 HRS.
7. Explain how Hepatorenal Syndrome advances and can lead to renal failure.
8. Investigate the benefits and risks of various HRS treatment approaches.
9. Advise patients and their families on the most efficacious therapies for Hepatorenal.
10. Syndrome to minimize further damage to the liver and kidneys.

Registration Fees
There is no fee to attend this event but advance registration is requested to allow for event planning.

To Register
Click on a date and location below to register for a program.

If online registration has closed you may still attend the event by registering as a walk-in the day of the program.

March 10, 2022 - Westminster, CA
Venue – TBA
Faculty: Paul Pockros, MD - Scripps Health
View the Course Flyer (Available Soon)

April 14, 2022 - Gainesville, FL
Venue - University of FL Health Sciences Center
Faculty: Paul Martin, MD - University of Miami
View the Course Flyer (Available Soon)

May 10, 2022 - La Jolla, CA

Venue – Scripps Green Hospital
Faculty: Catherine Frenette, MD - Scripps Health
the Course Flyer (Available Soon)

June 9, 2022 - Fresno, CA
Venue - St.  Agnes Hospital
Faculty: Robert Gish, MD - Hepatitis B Foundation
View the Course Flyer (Available Soon)

September 7, 2022 - Fall Church, VA
Venue – TBA
Faculty: Kirti Shetty, MD - University of Maryland
View the Course Flyer (Available Soon)

Joint Provider Statement
UofL CMEPD logoThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortium. The University of Louisville School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

 Designation Statement
The University of Louisville School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 1.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1253. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content. Completion criteria to obtain CE's: Attend entire session and complete the evaluation.

Jointly Provided By


Disclosure of Ineligible Company Support
This activity has been supported by an educational grants from Mallinckrodt.

Accreditation Disclosure
As a provider accredited by the ACCME, the Office of CME&PD, School of Medicine, University of Louisville, must ensure balance, independence, objectivity, and scientific rigor in all its accredited educational activities. All Planners, faculty, reviewers, and other persons that affected the content of this CME activity were required to submit a financial disclosure form from which relevant conflicts of interest were determined. If any relevant financial relationship(s) with ineligible companies were disclosed, the materials each of them prepared for this program (or influenced) were peer-reviewed and determined to be without ineligible company bias, were considered fair and balanced in terms of therapeutic options, and presented evidence-based content. All relevant financial relationships with ineligible organizations have been mitigated prior to this activity.

Learner Consent Statement
Names or contact information of learners will not be shared with any ineligible company or its agents without the explicit consent of the individual learner.